Valuation : Alector, Inc.

Market Cap 25Cr 22Cr 21Cr 19Cr 35Cr 2.41TCr 35Cr 243.39Cr 94Cr 1.23TCr 95Cr 93Cr 3.89TCr P/E 2026 *
-2.64x
P/E 2027 * -3.26x
Enterprise Value 2.6Cr 2.24Cr 2.11Cr 1.92Cr 3.59Cr 247.34Cr 3.6Cr 25Cr 9.65Cr 126.01Cr 9.76Cr 9.55Cr 399.19Cr EV / Sales 2026 *
2.37x
EV / Sales 2027 * -1.65x
Free-Float
90.47%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Alector, Inc.

1 day-8.10%
1 week-16.54%
Current month+0.44%
1 month+27.53%
3 months+39.26%
6 months+3.65%
Current year+45.51%
1 week 2.25
Extreme 2.25
2.61
1 month 1.65
Extreme 1.65
2.76
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27.05
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Sell

Controller/Auditor

-3,625 0.0032%
03/09/26 Sell

Chief Financial Officer

-29,251 0.0262%
03/09/26 Sell

Founder

-72,606 0.0650%
Change 5-day change 1-year change 3-year change Capi.($)
-8.10%-16.54%-18.93%-60.18% 25Cr
-0.94%-0.71%+45.60%+103.25% 6.85TCr
-0.53%-5.68%+31.23%+75.03% 6.29TCr
+3.13%+1.71%-12.50%+390.48% 2.81TCr
-2.78%-6.19%+26.49%+11.38% 2.56TCr
-0.54%-5.47%-3.88%-18.31% 2.47TCr
-1.19%-3.64%+19.67%-18.33% 1.98TCr
-4.27%+3.07%+211.22%+362.48% 1.77TCr
-2.00%-5.31%-6.01%+502.30% 1.47TCr
+1.14%-0.34%+52.38%+163.82% 1.45TCr
Average -1.62%-3.12%+34.53%+151.19% 2.77TCr
Weighted average by Cap. -0.75%-1.88%+36.55%+138.76%

Financials

2026 *2027 *
Net sales 1.1Cr 94.45L 88.93L 81.03L 1.52Cr 104.45Cr 1.52Cr 11Cr 4.07Cr 53Cr 4.12Cr 4.03Cr 168.57Cr 2.62Cr 2.25Cr 2.12Cr 1.93Cr 3.61Cr 249Cr 3.63Cr 25Cr 9.71Cr 126.85Cr 9.83Cr 9.61Cr 401.87Cr
Net income -9.69Cr -8.33Cr -7.85Cr -7.15Cr -13Cr -921.65Cr -13Cr -93Cr -36Cr -469.54Cr -36Cr -36Cr -1.49TCr -9.8Cr -8.44Cr -7.94Cr -7.24Cr -14Cr -932.86Cr -14Cr -94Cr -36Cr -475.25Cr -37Cr -36Cr -1.51TCr
Net Debt -23Cr -20Cr -18Cr -17Cr -31Cr -2.16TCr -32Cr -218.43Cr -84Cr -1.1TCr -85Cr -84Cr -3.49TCr -30Cr -26Cr -24Cr -22Cr -41Cr -2.82TCr -41Cr -284.98Cr -110.14Cr -1.44TCr -111.44Cr -109.01Cr -4.56TCr
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
09/26/09 $2.270 -8.10% 5,05,801
08/26/08 $2.470 +0.41% 9,16,854
04/26/04 $2.460 -1.99% 4,96,601
03/26/03 $2.510 -7.72% 27,92,296
02/26/02 $2.720 +13.33% 16,72,778
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.270USD
Average target price
3.100USD
Spread / Average Target
+36.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!